BRWM
ADAP

B. Riley Wealth Management’s Adaptimmune Therapeutics ADAP Stock Holding History

B. Riley Wealth Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,900
Closed -$148K – 349
2018
Q3 		$148K Buy
+10,900
New +$114K 0.04% 297

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

B. Riley Wealth Management's ADAP Position: Q4 2018 in Review

B. Riley Wealth Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2018, closing a stake of 10,900 shares — an estimated $148K sold.

B. Riley Wealth Management first reported a position in ADAP in Q3 2018 and held it in 1 quarter. The position peaked at $148K in Q3 2018. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2018.

  • B. Riley Wealth Management reported no remaining Adaptimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
  • B. Riley Wealth Management sold 10,900 Adaptimmune Therapeutics shares in Q4 2018, an estimated $148K.
  • B. Riley Wealth Management first reported a position in Adaptimmune Therapeutics in Q3 2018 and held it in 1 quarter.
  • B. Riley Wealth Management's Adaptimmune Therapeutics position peaked at $148K in Q3 2018.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2018.

Based on B. Riley Wealth Management's 13F filing for Q4 2018, filed 19 Feb 2019.